Title(s):
Professor of Radiology and Radiological Science
Professor of Oncology
Professor of Oncology
Appointment Phone:
410-955-6500
Primary Location:
Johns Hopkins Outpatient Center
Expertise:
Nuclear Medicine
Education and Experience
Training
- Washington University School of Medicine (St Louis MO)/ (1978)
Residencies
- Mallinckrodt Institute of Radiology (St Louis MO)/ Diagnostic Radiology (1982)
Fellowships
- Mallinckrodt Institute of Radiology (St Louis MO)/ Nuclear Medicine (1983)
Certifications
- Nuclear Medicine, American Board of Nuclear Medicine (1985)
- Nuclear Radiology, American Board of Radiology (1983)
- Diagnostic Radiology, American Board of Radiology (1982)
Locations
Johns Hopkins Outpatient Center
601 N. Caroline Street
Baltimore, MD 21287
Appointment Phone: 410-955-6500
Location Map
Department / Division
- Radiology and Radiological Science
Centers/Institutes
Centers / Institutes
- Esophageal Cancer Program
- Sidney Kimmel Comprehensive Cancer Center
Bio
Expertise
- Nuclear Medicine
Research
Research and Publications
Barrington, S.F.; Wahl, R.L.; Maisey, M. Atlas of clinical positron emission tomography. 2nd ed. London and New York: Oxford University Press; 2006. 424 p. p.
Chatzifotiadis, D.N.; Buchanan, J.W.; Wahl, R.L. Positron Emission Tomography and Cancer. In: Chang, A.E.; Ganz, P.A.; Hayes, D.F.; Kinsella, T.; Pass, H.I.; Schiller, J.H.; Stone, R.M.; Strecher, V., editors, Oncology: An Evidence-Based Approach. New York, NY: Springer Science and Business Media, Inc.; 2006.
Cho, S.Y.; Polster, J.; Engles, J.M.; Hilton, J.; Abraham, E.H.; Wahl, R.L. In vitro evaluation of adenosine 5''-monophosphate as an imaging agent of tumor metabolism. J Nucl Med. 2006 May;47(5):837-845.
Goetze, S.; Pannu, H.K.; Wahl, R.L. Clinically significant abnormal findings on the "nondiagnostic" CT portion of low-amperage-CT attenuation-corrected myocardial perfusion SPECT/CT studies. J Nucl Med. 2006 Aug;47(8):1312-1318.
Ha, P.K.; Hdeib, A.; Goldenberg, D.; Jacene, H.; Patel, P.; Koch, W.; Califano, J.; Cummings, C.W.; Flint, P.W.; Wahl, R.; Tufano, R.P. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006 Jan;132(1):12-16.
Jacene, H.A.; Ishimori, T.; Engles, J.M.; Leboulleux, S.; Stearns, V.; Wahl, R.L. Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med. 2006 Jun;47(6):950-956.
Jacene, H.A.; Stearns, V.; Wahl, R.L. Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT. Clinical nuclear medicine. 2006 Jul;31(7):379-381.
Sgouros, G.; Song, H.; Ladenson, P.W.; Wahl, R.L. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. J Nucl Med. 2006 Dec;47(12):1977-1984.
Song, H.; He, B.; Prideaux, A.; Du, Y.; Frey, E.; Kasecamp, W.; Ladenson, P.W.; Wahl, R.L.; Sgouros, G. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006 Dec;47(12):1985-1994.
Tatsumi, M.; Cohade, C.; Mourtzikos, K.A.; Fishman, E.K.; Wahl, R.L. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):254-262.
Fuchs, E.J.; Lee, L.A.; Torbenson, M.S.; Parsons, T.L.; Bakshi, R.P.; Guidos, A.M.; Wahl, R.L.; Hendrix, C.W. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis. 2007 Mar 1;195(5):703-710.
Goetze, S.; Wahl, R.L. Prevalence of misregistration between SPECT and CT for attenuation-corrected myocardial perfusion SPECT. J Nucl Cardiol. 2007 Apr;14(2):200-206.
Jacene, H.A.; Filice, R.; Kasecamp, W.; Wahl, R.L. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007 Nov;48(11):1767-1776.
Kasamon, Y.L.; Jones, R.J.; Wahl, R.L. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med. 2007 Jan;48 Suppl 1:19S-27S.
Kelloff, G.J.; Sullivan, D.M.; Wilson, W.; Cheson, B.; Juweid, M.; Mills, G.Q.; Zelenetz, A.D.; Horning, S.J.; Weber, W.; Sargent, D.J.; Dodd, L.; Korn, E.; Armitage, J.; Schilsky, R.; Christian, M.; O''Connor O, A.; Wang, S.J.; Farrell, A.T.; Pazdur, R.; Graham, M.; Wahl, R.L.; Larson, S.M.; Kostakoglu, L.; Daube-Witherspoon, M.; Gastonis, C.; Siegel, B.A.; Shankar, L.K.; Lee, D.B.; Higley, H.R.; Sigman, C.C.; Carucci, D.; Timko, D.; Degennaro, L.J.; Sigal, E.; Barker, A.; Woodcock, J. FDG-PET Lymphoma Demonstration Project Invitational Workshop. Acad Radiol. 2007 Mar;14(3):330-339.
Prideaux, A.R.; Song, H.; Hobbs, R.F.; He, B.; Frey, E.C.; Ladenson, P.W.; Wahl, R.L.; Sgouros, G. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med. 2007 Jun;48(6):1008-1016.
Song, H.; Du, Y.; Sgouros, G.; Prideaux, A.; Frey, E.; Wahl, R.L. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin''s lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. J Nucl Med. 2007 Jan;48(1):150-157.
Ford, E.C.; Lavely, W.C.; Frassica, D.A.; Myers, L.T.; Asrari, F.; Wahl, R.L.; Zellars, R.C. Comparison of FDG-PET/CT and CT for delineation of lumpectomy cavity for partial breast irradiation. Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):595-602.
Goetze, S.; Lavely, W.C.; Ziessman, H.A.; Wahl, R.L. Visualization of brown adipose tissue with 99mTc-methoxyisobutylisonitrile on SPECT/CT. J Nucl Med. 2008 May;49(5):752-756.
He, B.; Wahl, R.L.; Du, Y.; Sgouros, G.; Jacene, H.; Flinn, I.; Frey, E.C. Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning-Monte Carlo simulation studies. IEEE Trans Med Imaging. 2008 Apr;27(4):521-530.
Jacene, H.A.; Goudarzi, B.; Wahl, R.L. Scalene muscle uptake: a potential pitfall in head and neck PET/CT. Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):89-94.
Kapadia, N.S.; Engles, J.M.; Wahl, R.L. In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. J Nucl Med. 2008 Apr;49(4):674-678.
Kasamon, Y.L.; Wahl, R.L. FDG PET and risk-adapted therapy in Hodgkin''s and non-Hodgkin''s lymphoma. Curr Opin Oncol. 2008 Mar;20(2):206-219.
Lodge, M.A.; Jacene, H.A.; Pili, R.; Wahl, R.L. Reproducibility of tumor blood flow quantification with 15O-water PET. J Nucl Med. 2008 Oct;49(10):1620-1627.
Sgouros, G.; Frey, E.; Wahl, R.; He, B.; Prideaux, A.; Hobbs, R. Three-dimensional imaging-based radiobiological dosimetry. Seminars in nuclear medicine. 2008 Sep;38(5):321-334.
Wahl, R.L. Individualizing cancer therapies using "anatomolecular" imaging. J Nucl Med. 2008 Jun;49(6):65N-68N.
Buijs, M.; Vossen, J.A.; Geschwind, J.F.; Ishimori, T.; Engles, J.M.; Acha-Ngwodo, O.; Wahl, R.L.; Vali, M. Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest New Drugs. 2009 Apr;27(2):120-123.
Ford, E.C.; Herman, J.; Yorke, E.; Wahl, R.L. 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med. 2009 Oct;50(10):1655-1665.
He, B.; Du, Y.; Segars, W.P.; Wahl, R.L.; Sgouros, G.; Jacene, H.; Frey, E.C. Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. Med Phys. 2009 Feb;36(2):612-619.
He, B.; Wahl, R.L.; Sgouros, G.; Du, Y.; Jacene, H.; Kasecamp, W.R.; Flinn, I.; Hammes, R.J.; Bianco, J.; Kahl, B.; Frey, E.C. Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning-patient studies. Med Phys. 2009 May;36(5):1595-1601.
Hobbs, R.F.; Wahl, R.L.; Lodge, M.A.; Javadi, M.S.; Cho, S.Y.; Chien, D.T.; Ewertz, M.E.; Esaias, C.E.; Ladenson, P.W.; Sgouros, G. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med. 2009 Nov;50(11):1844-1847.
Jacene, H.A.; Filice, R.; Kasecamp, W.; Wahl, R.L. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med. 2009 Jan;50(1):8-17.
Jacene, H.A.; Leboulleux, S.; Baba, S.; Chatzifotiadis, D.; Goudarzi, B.; Teytelbaum, O.; Horton, K.M.; Kamel, I.; Macura, K.J.; Tsai, H.L.; Kowalski, J.; Wahl, R.L. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med. 2009 Nov;50(11):1760-1769.
Kasamon, Y.L.; Wahl, R.L.; Ziessman, H.A.; Blackford, A.L.; Goodman, S.N.; Fidyk, C.A.; Rogers, K.M.; Bolanos-Meade, J.; Borowitz, M.J.; Ambinder, R.F.; Jones, R.J.; Swinnen, L.J. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant. 2009 Feb;15(2):242-248.
Lodge, M.A.; Rahmim, A.; Wahl, R.L. A practical, automated quality assurance method for measuring spatial resolution in PET. J Nucl Med. 2009 Aug;50(8):1307-1314.
Ma, W.W.; Jacene, H.; Song, D.; Vilardell, F.; Messersmith, W.A.; Laheru, D.; Wahl, R.; Endres, C.; Jimeno, A.; Pomper, M.G.; Hidalgo, M. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009 Jun 1;27(16):2697-2704.
Terrovitis, J.; Lautamaki, R.; Bonios, M.; Fox, J.; Engles, J.M.; Yu, J.; Leppo, M.K.; Pomper, M.G.; Wahl, R.L.; Seidel, J.; Tsui, B.M.; Bengel, F.M.; Abraham, M.R.; Marban, E. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. Journal of the American College of Cardiology. 2009 Oct 20;54(17):1619-1626.
Baba, S.; Jacene, H.A.; Engles, J.M.; Honda, H.; Wahl, R.L. CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies. J Nucl Med. 2010 Feb;51(2):246-250.
Baechler, S.; Hobbs, R.F.; Jacene, H.A.; Bochud, F.O.; Wahl, R.L.; Sgouros, G. Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. J Nucl Med. 2010 Dec;51(12):1878-1884.
Bonta, D.V.; Wahl, R.L. Overcorrection of iodinated contrast attenuation in SPECT-CT: phantom studies. Med Phys. 2010 Sep;37(9):4897-4901.
Goudarzi, B.; Jacene, H.A.; Wahl, R.L. Measuring the "unmeasurable": assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma. Acad Radiol. 2010 Sep;17(9):1175-1185.
Heston, T.F.; Wahl, R.L. Molecular imaging in thyroid cancer. Cancer Imaging. 2010;10(1):1-7.
Hobbs, R.F.; Baechler, S.; Wahl, R.L.; He, B.; Song, H.; Esaias, C.E.; Frey, E.C.; Jacene, H.; Sgouros, G. Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy. J Nucl Med. 2010 Mar;51(3):368-375.
Hobbs, R.F.; McNutt, T.; Baechler, S.; He, B.; Esaias, C.E.; Frey, E.C.; Loeb, D.M.; Wahl, R.L.; Shokek, O.; Sgouros, G. A Treatment Planning Method for Sequentially Combining Radiopharmaceutical Therapy and External Radiation Therapy. Int J Radiat Oncol Biol Phys. 2010 Oct 13.
Jacene, H.A.; Cohade, C.C.; Zhang, Z.; Wahl, R.L. The Relationship between Patients'' Serum Glucose Levels and Metabolically Active Brown Adipose Tissue Detected by PET/CT. Mol Imaging Biol. 2010 Dec 8.
Lodge, M.A.; Chaudhry, M.A.; Udall, D.N.; Wahl, R.L. Characterization of a perirectal artifact in 18F-FDG PET/CT. J Nucl Med. 2010 Oct;51(10):1501-1506.
Lodge, M.A.; Rahmim, A.; Wahl, R.L. Simultaneous measurement of noise and spatial resolution in PET phantom images. Phys Med Biol. 2010 Feb 21;55(4):1069-1081.
Schaefer, N.G.; Ma, J.; Huang, P.; Buchanan, J.; Wahl, R.L. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists. J Nucl Med. 2010 Jun;51(6):987-994.
Graham, M.M.; Badawi, R.D.; Wahl, R.L. Variations in PET/CT Methodology for Oncologic Imaging at U.S. Academic Medical Centers: An Imaging Response Assessment Team Survey. J Nucl Med. 2011 Feb;52(2):311-317.
Liapi, E.; JF, H.G.; Vali, M.; Khwaja, A.A.; Prieto-Ventura, V.; Buijs, M.; Vossen, J.A.; Ganapathy, S.; Wahl, R.L. Assessment of Tumoricidal Efficacy and Response to Treatment with 18F-FDG PET/CT After Intraarterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor. J Nucl Med. 2011 Feb;52(2):225-230.
Chatzifotiadis, D.N.; Buchanan, J.W.; Wahl, R.L. Positron Emission Tomography and Cancer. In: Chang, A.E.; Ganz, P.A.; Hayes, D.F.; Kinsella, T.; Pass, H.I.; Schiller, J.H.; Stone, R.M.; Strecher, V., editors, Oncology: An Evidence-Based Approach. New York, NY: Springer Science and Business Media, Inc.; 2006.
Cho, S.Y.; Polster, J.; Engles, J.M.; Hilton, J.; Abraham, E.H.; Wahl, R.L. In vitro evaluation of adenosine 5''-monophosphate as an imaging agent of tumor metabolism. J Nucl Med. 2006 May;47(5):837-845.
Goetze, S.; Pannu, H.K.; Wahl, R.L. Clinically significant abnormal findings on the "nondiagnostic" CT portion of low-amperage-CT attenuation-corrected myocardial perfusion SPECT/CT studies. J Nucl Med. 2006 Aug;47(8):1312-1318.
Ha, P.K.; Hdeib, A.; Goldenberg, D.; Jacene, H.; Patel, P.; Koch, W.; Califano, J.; Cummings, C.W.; Flint, P.W.; Wahl, R.; Tufano, R.P. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006 Jan;132(1):12-16.
Jacene, H.A.; Ishimori, T.; Engles, J.M.; Leboulleux, S.; Stearns, V.; Wahl, R.L. Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med. 2006 Jun;47(6):950-956.
Jacene, H.A.; Stearns, V.; Wahl, R.L. Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT. Clinical nuclear medicine. 2006 Jul;31(7):379-381.
Sgouros, G.; Song, H.; Ladenson, P.W.; Wahl, R.L. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. J Nucl Med. 2006 Dec;47(12):1977-1984.
Song, H.; He, B.; Prideaux, A.; Du, Y.; Frey, E.; Kasecamp, W.; Ladenson, P.W.; Wahl, R.L.; Sgouros, G. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006 Dec;47(12):1985-1994.
Tatsumi, M.; Cohade, C.; Mourtzikos, K.A.; Fishman, E.K.; Wahl, R.L. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):254-262.
Fuchs, E.J.; Lee, L.A.; Torbenson, M.S.; Parsons, T.L.; Bakshi, R.P.; Guidos, A.M.; Wahl, R.L.; Hendrix, C.W. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis. 2007 Mar 1;195(5):703-710.
Goetze, S.; Wahl, R.L. Prevalence of misregistration between SPECT and CT for attenuation-corrected myocardial perfusion SPECT. J Nucl Cardiol. 2007 Apr;14(2):200-206.
Jacene, H.A.; Filice, R.; Kasecamp, W.; Wahl, R.L. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007 Nov;48(11):1767-1776.
Kasamon, Y.L.; Jones, R.J.; Wahl, R.L. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med. 2007 Jan;48 Suppl 1:19S-27S.
Kelloff, G.J.; Sullivan, D.M.; Wilson, W.; Cheson, B.; Juweid, M.; Mills, G.Q.; Zelenetz, A.D.; Horning, S.J.; Weber, W.; Sargent, D.J.; Dodd, L.; Korn, E.; Armitage, J.; Schilsky, R.; Christian, M.; O''Connor O, A.; Wang, S.J.; Farrell, A.T.; Pazdur, R.; Graham, M.; Wahl, R.L.; Larson, S.M.; Kostakoglu, L.; Daube-Witherspoon, M.; Gastonis, C.; Siegel, B.A.; Shankar, L.K.; Lee, D.B.; Higley, H.R.; Sigman, C.C.; Carucci, D.; Timko, D.; Degennaro, L.J.; Sigal, E.; Barker, A.; Woodcock, J. FDG-PET Lymphoma Demonstration Project Invitational Workshop. Acad Radiol. 2007 Mar;14(3):330-339.
Prideaux, A.R.; Song, H.; Hobbs, R.F.; He, B.; Frey, E.C.; Ladenson, P.W.; Wahl, R.L.; Sgouros, G. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med. 2007 Jun;48(6):1008-1016.
Song, H.; Du, Y.; Sgouros, G.; Prideaux, A.; Frey, E.; Wahl, R.L. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin''s lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. J Nucl Med. 2007 Jan;48(1):150-157.
Ford, E.C.; Lavely, W.C.; Frassica, D.A.; Myers, L.T.; Asrari, F.; Wahl, R.L.; Zellars, R.C. Comparison of FDG-PET/CT and CT for delineation of lumpectomy cavity for partial breast irradiation. Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):595-602.
Goetze, S.; Lavely, W.C.; Ziessman, H.A.; Wahl, R.L. Visualization of brown adipose tissue with 99mTc-methoxyisobutylisonitrile on SPECT/CT. J Nucl Med. 2008 May;49(5):752-756.
He, B.; Wahl, R.L.; Du, Y.; Sgouros, G.; Jacene, H.; Flinn, I.; Frey, E.C. Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning-Monte Carlo simulation studies. IEEE Trans Med Imaging. 2008 Apr;27(4):521-530.
Jacene, H.A.; Goudarzi, B.; Wahl, R.L. Scalene muscle uptake: a potential pitfall in head and neck PET/CT. Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):89-94.
Kapadia, N.S.; Engles, J.M.; Wahl, R.L. In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. J Nucl Med. 2008 Apr;49(4):674-678.
Kasamon, Y.L.; Wahl, R.L. FDG PET and risk-adapted therapy in Hodgkin''s and non-Hodgkin''s lymphoma. Curr Opin Oncol. 2008 Mar;20(2):206-219.
Lodge, M.A.; Jacene, H.A.; Pili, R.; Wahl, R.L. Reproducibility of tumor blood flow quantification with 15O-water PET. J Nucl Med. 2008 Oct;49(10):1620-1627.
Sgouros, G.; Frey, E.; Wahl, R.; He, B.; Prideaux, A.; Hobbs, R. Three-dimensional imaging-based radiobiological dosimetry. Seminars in nuclear medicine. 2008 Sep;38(5):321-334.
Wahl, R.L. Individualizing cancer therapies using "anatomolecular" imaging. J Nucl Med. 2008 Jun;49(6):65N-68N.
Buijs, M.; Vossen, J.A.; Geschwind, J.F.; Ishimori, T.; Engles, J.M.; Acha-Ngwodo, O.; Wahl, R.L.; Vali, M. Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest New Drugs. 2009 Apr;27(2):120-123.
Ford, E.C.; Herman, J.; Yorke, E.; Wahl, R.L. 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med. 2009 Oct;50(10):1655-1665.
He, B.; Du, Y.; Segars, W.P.; Wahl, R.L.; Sgouros, G.; Jacene, H.; Frey, E.C. Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. Med Phys. 2009 Feb;36(2):612-619.
He, B.; Wahl, R.L.; Sgouros, G.; Du, Y.; Jacene, H.; Kasecamp, W.R.; Flinn, I.; Hammes, R.J.; Bianco, J.; Kahl, B.; Frey, E.C. Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning-patient studies. Med Phys. 2009 May;36(5):1595-1601.
Hobbs, R.F.; Wahl, R.L.; Lodge, M.A.; Javadi, M.S.; Cho, S.Y.; Chien, D.T.; Ewertz, M.E.; Esaias, C.E.; Ladenson, P.W.; Sgouros, G. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med. 2009 Nov;50(11):1844-1847.
Jacene, H.A.; Filice, R.; Kasecamp, W.; Wahl, R.L. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med. 2009 Jan;50(1):8-17.
Jacene, H.A.; Leboulleux, S.; Baba, S.; Chatzifotiadis, D.; Goudarzi, B.; Teytelbaum, O.; Horton, K.M.; Kamel, I.; Macura, K.J.; Tsai, H.L.; Kowalski, J.; Wahl, R.L. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med. 2009 Nov;50(11):1760-1769.
Kasamon, Y.L.; Wahl, R.L.; Ziessman, H.A.; Blackford, A.L.; Goodman, S.N.; Fidyk, C.A.; Rogers, K.M.; Bolanos-Meade, J.; Borowitz, M.J.; Ambinder, R.F.; Jones, R.J.; Swinnen, L.J. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant. 2009 Feb;15(2):242-248.
Lodge, M.A.; Rahmim, A.; Wahl, R.L. A practical, automated quality assurance method for measuring spatial resolution in PET. J Nucl Med. 2009 Aug;50(8):1307-1314.
Ma, W.W.; Jacene, H.; Song, D.; Vilardell, F.; Messersmith, W.A.; Laheru, D.; Wahl, R.; Endres, C.; Jimeno, A.; Pomper, M.G.; Hidalgo, M. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009 Jun 1;27(16):2697-2704.
Terrovitis, J.; Lautamaki, R.; Bonios, M.; Fox, J.; Engles, J.M.; Yu, J.; Leppo, M.K.; Pomper, M.G.; Wahl, R.L.; Seidel, J.; Tsui, B.M.; Bengel, F.M.; Abraham, M.R.; Marban, E. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. Journal of the American College of Cardiology. 2009 Oct 20;54(17):1619-1626.
Baba, S.; Jacene, H.A.; Engles, J.M.; Honda, H.; Wahl, R.L. CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies. J Nucl Med. 2010 Feb;51(2):246-250.
Baechler, S.; Hobbs, R.F.; Jacene, H.A.; Bochud, F.O.; Wahl, R.L.; Sgouros, G. Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. J Nucl Med. 2010 Dec;51(12):1878-1884.
Bonta, D.V.; Wahl, R.L. Overcorrection of iodinated contrast attenuation in SPECT-CT: phantom studies. Med Phys. 2010 Sep;37(9):4897-4901.
Goudarzi, B.; Jacene, H.A.; Wahl, R.L. Measuring the "unmeasurable": assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma. Acad Radiol. 2010 Sep;17(9):1175-1185.
Heston, T.F.; Wahl, R.L. Molecular imaging in thyroid cancer. Cancer Imaging. 2010;10(1):1-7.
Hobbs, R.F.; Baechler, S.; Wahl, R.L.; He, B.; Song, H.; Esaias, C.E.; Frey, E.C.; Jacene, H.; Sgouros, G. Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy. J Nucl Med. 2010 Mar;51(3):368-375.
Hobbs, R.F.; McNutt, T.; Baechler, S.; He, B.; Esaias, C.E.; Frey, E.C.; Loeb, D.M.; Wahl, R.L.; Shokek, O.; Sgouros, G. A Treatment Planning Method for Sequentially Combining Radiopharmaceutical Therapy and External Radiation Therapy. Int J Radiat Oncol Biol Phys. 2010 Oct 13.
Jacene, H.A.; Cohade, C.C.; Zhang, Z.; Wahl, R.L. The Relationship between Patients'' Serum Glucose Levels and Metabolically Active Brown Adipose Tissue Detected by PET/CT. Mol Imaging Biol. 2010 Dec 8.
Lodge, M.A.; Chaudhry, M.A.; Udall, D.N.; Wahl, R.L. Characterization of a perirectal artifact in 18F-FDG PET/CT. J Nucl Med. 2010 Oct;51(10):1501-1506.
Lodge, M.A.; Rahmim, A.; Wahl, R.L. Simultaneous measurement of noise and spatial resolution in PET phantom images. Phys Med Biol. 2010 Feb 21;55(4):1069-1081.
Schaefer, N.G.; Ma, J.; Huang, P.; Buchanan, J.; Wahl, R.L. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists. J Nucl Med. 2010 Jun;51(6):987-994.
Graham, M.M.; Badawi, R.D.; Wahl, R.L. Variations in PET/CT Methodology for Oncologic Imaging at U.S. Academic Medical Centers: An Imaging Response Assessment Team Survey. J Nucl Med. 2011 Feb;52(2):311-317.
Liapi, E.; JF, H.G.; Vali, M.; Khwaja, A.A.; Prieto-Ventura, V.; Buijs, M.; Vossen, J.A.; Ganapathy, S.; Wahl, R.L. Assessment of Tumoricidal Efficacy and Response to Treatment with 18F-FDG PET/CT After Intraarterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor. J Nucl Med. 2011 Feb;52(2):225-230.
More Info
Languages
- English
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts